BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Prostate cancer AND EPAS1, MOP2, 2034, ENSG00000116016, PASD2, HIF2A, Q99814 AND Treatment
7 results:

  • 1. Radiological imaging protection: a study on imaging dose used while planning computed tomography for external radiotherapy in Japan.
    Kito S; Suda Y; Tanabe S; Takizawa T; Nagahata T; Tohyama N; Okamoto H; Kodama T; Fujita Y; Miyashita H; Shinoda K; Kurooka M; Shimizu H; Ohno T; Sakamoto M
    J Radiat Res; 2024 Mar; 65(2):159-167. PubMed ID: 38151953
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Genitourinary cancers updates: highlights from ASCO 2023.
    Qin Q; Sheffield H; Taasan SM; Wang AZ; Zhang T
    J Hematol Oncol; 2023 Nov; 16(1):112. PubMed ID: 37990343
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. [Precision oncology options in urological cancers].
    Franz A; Plage H; Fendler A; Schlomm T; Kornienko K
    Urologie; 2023 Jul; 62(7):696-704. PubMed ID: 37294331
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. LncRNA H19 promotes tumor angiogenesis in smokers by targeting anti-angiogenic miRNAs.
    Shirvaliloo M
    Epigenomics; 2023 Jan; 15(2):61-73. PubMed ID: 36802727
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Tumor suppressor role of RBM22 in prostate cancer acting as a dual-factor regulating alternative splicing and transcription of key oncogenic genes.
    Jiménez-Vacas JM; Montero-Hidalgo AJ; Gómez-Gómez E; Sáez-Martínez P; Fuentes-Fayos AC; Closa A; González-Serrano T; Martínez-López A; Sánchez-Sánchez R; López-Casas PP; Sarmento-Cabral A; Olmos D; Eyras E; Castaño JP; Gahete MD; Luque RM
    Transl Res; 2023 Mar; 253():68-79. PubMed ID: 36089245
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Incidence and mortality projections for major cancers among Korean men until 2034, with a focus on prostate cancer.
    Pak S; Jung KW; Park EH; Ko YH; Won YJ; Joung JY
    Investig Clin Urol; 2022 Mar; 63(2):175-183. PubMed ID: 35244991
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Patient Preference Between Cabazitaxel and Docetaxel for First-line Chemotherapy in Metastatic Castration-resistant prostate cancer: The CABADOC Trial.
    Baciarello G; Delva R; Gravis G; Tazi Y; Beuzeboc P; Gross-Goupil M; Bompas E; Joly F; Greilsamer C; Hon TNT; Barthelemy P; Culine S; Berdah JF; Deblock M; Ratta R; Flechon A; Cheneau C; Maillard A; Martineau G; Borget I; Fizazi K;
    Eur Urol; 2022 Mar; 81(3):234-240. PubMed ID: 34789394
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.